Avacta Group Plc – LSE:AVCT.L

Avacta Group stock price today

GBP 126.4
+77.4
+157.96%
Financial Health
0
1
2
3
4
5
6
7
8
9

Avacta Group stock price monthly change

-38.75%
month

Avacta Group stock price quarterly change

-38.75%
quarter

Avacta Group stock price yearly change

-56.44%
year

Avacta Group key metrics

Market Cap
171.01M
Enterprise value
8.90B
P/E
-12.27
EV/Sales
2353.89
EV/EBITDA
-1028.74
Price/Sales
23.35
Price/Book
2.45
PEG ratio
0.47
EPS
-0.24
Revenue
32.9M
EBITDA
-45.56M
Income
-64.44M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-250.32%
Oper. margin
-290.64%
Gross margin
76.16%
EBIT margin
-290.64%
EBITDA margin
-138.5%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Avacta Group stock price history

Avacta Group stock forecast

Avacta Group financial statements

Avacta Group Plc (LSE:AVCT.L): Profit margin
Jun 2022 5.51M -8.93M -162.03%
Dec 2022 4.13M -30.55M -738.83%
Jun 2023 11.88M -11.53M -97%
Dec 2023 11.35M -13.41M -118.11%
Avacta Group Plc (LSE:AVCT.L): Analyst Estimates
2027 28.71M -30.33M -105.66%
  • Analysts Price target

  • Financials & Ratios estimates

Avacta Group Plc (LSE:AVCT.L): Debt to assets
Jun 2022 45461000 9.47M 20.85%
Dec 2022 92649000 74.21M 80.1%
Jun 2023 87748000 65.01M 74.09%
Dec 2023 73191000 51.38M 70.21%
Avacta Group Plc (LSE:AVCT.L): Cash Flow
Jun 2022 -5.50M -4.03M 368K
Dec 2022 -10.93M -21.00M 56.53M
Jun 2023 -8.04M -7.35M -561K
Dec 2023 -6.82M -1.65M -737K

Avacta Group alternative data

Avacta Group Plc (LSE:AVCT.L): Employee count
Aug 2023 120
Sep 2023 120
Oct 2023 120
Nov 2023 120
Dec 2023 120
Jan 2024 120
Feb 2024 120
Mar 2024 120
Apr 2024 120
May 2024 120
Jun 2024 120
Jul 2024 154

Avacta Group other data

Insider Compensation
Mr. Tony Gardiner (1971) Chief Financial Officer, Company Sec. & Executive Director
$191,000
  • What's the price of Avacta Group stock today?

    One share of Avacta Group stock can currently be purchased for approximately $126.4.

  • When is Avacta Group's next earnings date?

    Unfortunately, Avacta Group's (AVCT.L) next earnings date is currently unknown.

  • Does Avacta Group pay dividends?

    No, Avacta Group does not pay dividends.

  • How much money does Avacta Group make?

    Avacta Group has a market capitalization of 171.01M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 140.83% to 23.25M US dollars.

  • What is Avacta Group's stock symbol?

    Avacta Group Plc is traded on the LSE under the ticker symbol "AVCT.L".

  • What is Avacta Group's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Avacta Group?

    Shares of Avacta Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Avacta Group's key executives?

    Avacta Group's management team includes the following people:

    • Mr. Tony Gardiner Chief Financial Officer, Company Sec. & Executive Director(age: 54, pay: $191,000)
  • How many employees does Avacta Group have?

    As Jul 2024, Avacta Group employs 154 workers, which is 28% more then previous month and 28% more then previous quarter.

  • When Avacta Group went public?

    Avacta Group Plc is publicly traded company for more then 21 years since IPO on 8 Sep 2003.

  • What is Avacta Group's official website?

    The official website for Avacta Group is avacta.com.

  • How can i contact Avacta Group?

    Avacta Group can be reached via phone at +44 1904 217070.

Avacta Group company profile:

Avacta Group Plc

avacta.com
Exchange:

LSE

Full time employees:

154

Industry:

Biotechnology

Sector:

Healthcare

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Thorp Arch Estate
Wetherby, LS23 7FA

:
ISIN: GB00BYYW9G87
CUSIP: G2967N117